pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Hematology · news · pharmadog
← back to Hematology
News · Hematology
637
stories
24d
mRNA cancer vaccines’ biggest barriers to market
biopharma dive
24d
Boycott launched against American Diabetes Association includes journal
stat
24d
Beyond clinical endpoints: Rethinking ALS drug development through disease biology
fiercebiotech
24d
STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGs
stat
25d
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
fiercebiotech
25d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
25d
The signal that changes everything: understanding MRD in oncology drug development
fiercebiotech
25d
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
biopharma dive
25d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
25d
A booming business on Wall Street would love more biotechs to quietly die
biopharma dive
25d
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
fiercebiotech
26d
August biopharma layoffs impact just over 500, down 90% year over year
biospace
26d
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
26d
STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea
stat
26d
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
27d
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
biopharma dive
27d
Roivant's pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
biospace
27d
Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T
endpoints
27d
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
biopharma dive
27d
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
fiercebiotech
27d
STAT+: Roivant lung disease drug hits mid-stage study goals
stat
27d
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
27d
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
stat
28d
BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
fiercebiotech
29d
AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies
fiercebiotech
Sep 6, 26
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win
fiercebiotech
Sep 4, 26
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
fiercebiotech
Sep 4, 26
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
fda press
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
biospace
← prev
page 5 of 22
next →
